Scythian Biosciences Announces Binding Agreement for Argentinian Acquisition of ABP

0
92

– ABP HOLDS FIRST & ONLY CANNABIS LICENSE IN ARGENTINA – – ABP REVENUES IN EXCESS OF USD$11 MILLION IN 2017 AND PROFITABLE – TORONTO, May 11, 2018 (GLOBE NEWSWIRE) — Scythian Biosciences Corp. (the “Company” or “Scythian”) (TSXV:SCYB) (Frankfurt:9SB) (OTC – Nasdaq Intl:SCCYF) is pleased to announce that the Company has entered into a business combination agreement (the “Agreement”) with MMJ International Investments Inc. (“MMJ” or “MMJ International”), owner of Argentina-based ABP S.A. (“ABP”), a pharmaceutical import and distribution company with a license to import, sell and distribute medical products and derivatives in Argentina. ABP also holds a license to import CBD oil into Argentina (the “License”). Scythian Biosciences Announces Binding Agreement for Argentinian Acquisition of ABP

thumbnail courtesy of ptcommunity.com

LEAVE A REPLY

Please enter your comment!
Please enter your name here